iShares Silver Trust vs Health Care Select Sector SPDR Fund — how do they compare? iShares Silver Trust trades at $54.86 (market cap $29.02B), while Health Care Select Sector SPDR Fund trades at $170.91 (market cap $43.48B). The key difference: Health Care Select Sector SPDR Fund is the larger of the two by market cap, and Health Care Select Sector SPDR Fund is trading nearer its 52-week high, iShares Silver Trust nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Silver Trust for 89 Days and Health Care Select Sector SPDR Fund for 100 Days on average.
| SLV | XLV | |
|---|---|---|
Market Cap | $29.02B | $43.48B |
Volume | 16,510,334 | 11,121,431 |
52-Week High | $105.57 | $175.68 |
52-Week Low | $42.40 | $141.95 |
Typical Hold Time | 89 Days | 100 Days |
Signals from Pluang's Aura AI — not financial advice
SLV trades at $55.06, up 2.3% over 24 hours, with a bearish technical signal from moving averages but neutral oscillators. The company reported $2.17M net income for 2024 despite zero revenue, with total assets surging to $13.41B from $10M in 2023. Recent news highlights silver price volatility driven by Fed policy expectations and Treasury yields.
The outlook is clouded by bearish technicals and macroeconomic pressures on silver, though low debt and asset growth offer stability. Risks include interest rate sensitivity and industrial demand fluctuations, while institutional sentiment remains cautious amid price declines.
XLV trades at $169.58 with a slight 0.46% daily gain amid bearish technical signals. The ETF faces selling pressure with moving averages indicating downward momentum while oscillators remain neutral. Recent news highlights XLV's competitive expense ratio of 0.08% and defensive healthcare sector positioning. Options activity shows increased put volume, suggesting some investor caution despite the fund's diversification across 61 healthcare stocks.
The healthcare ETF presents a cost-effective defensive play with potential upside if political volatility subsides post-elections. Key risks include sector-specific regulatory pressures and biotech trial failures impacting holdings. Current technical weakness near support at $166 requires monitoring for potential breakdown, though the fund's low fees and broad diversification provide stability during market uncertainty.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.
Read more on SLV →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →